S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models-Reference-Cited by-同舟云学术

S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models

Published:2024-08-28 Issue: Volume: Page:
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Pantano F.,Simonetti S.^ORCID,Iuliani M.^ORCID,Guillen M. J.^ORCID,Cuevas C.,Aviles P.,Cavaliere S.,Napolitano A.,Cortellini A.,Mazzocca A.,Nibid L.^ORCID,Sabarese G.,Perrone G.^ORCID,Gambarotti M.,Righi A.,Palmerini E.,Stacchiotti S.,Barisella M.,Gronchi A.,Valeri S.,Sbaraglia M.,Dei Tos A. P.,Tonini G.,Vincenzi B.

Funder

PharmaMar

PharMar

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41388-024-03143-9.pdf

Reference58 articles.

1. Mastrangelo G, Coindre JM, Ducimetière F, Dei Tos AP, Fadda E, Blay JY, et al. Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions. Cancer. 2012;118:5339–48.

2. Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv51–iv67.

3. Grünewald TG, Alonso M, Avnet S, Banito A, Burdach S, Cidre-Aranaz F, et al. Sarcoma treatment in the era of molecular medicine. EMBO Mol Med. 2020;12:e11131.

4. Samuels BL, Chawla S, Patel S, von Mehren M, Hamm J, Kaiser PE, et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol. 2013;24:1703–9.

5. Linch M, Miah AB, Thway K, Judson IR, Benson C. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nat Rev Clin Oncol. 2014;11:187–202.